Extended-Spectrum Azoles — Voriconazole, Posaconazole, and Isavuconazole

Voriconazole has oral bioavailability of approximately 96 percent under fasting conditions, one of its major advantages over itraconazole. It must be taken on an empty stomach because high-fat meals reduce the area under the concentration-time curve (AUC) by approximately 24 percent — a clinically meaningful reduction that is a practical source of subtherapeutic concentrations even when doses appear appropriate. The intravenous (IV) formulation uses sulfobutylether-beta-cyclodextrin (SBECD) as a solubilizing vehicle. SBECD accumulates in renal insufficiency and is renally excreted; when creatinine clearance falls below 50 mL/min, the IV formulation should be switched to oral voriconazole to avoid SBECD accumulation.

Voriconazole exhibits non-linear pharmacokinetics because its primary metabolizing enzyme, hepatic cytochrome P450 2C19 (CYP2C19), becomes saturated at therapeutic doses. Modest dose increases therefore produce disproportionately large increases in plasma exposure. CYP2C19 is genetically polymorphic: poor metabolizers (PM), who carry two loss-of-function alleles, achieve plasma concentrations four to five times higher than normal metabolizers at the same dose; ultrarapid metabolizers (UM) achieve concentrations up to 50 percent lower. The PM phenotype occurs in approximately three to five percent of European and African populations and 15 to 20 percent of Asian populations — a clinically decisive difference. CYP2C19 is also inhibited by proton pump inhibitors such as omeprazole, further complicating concentration prediction from dose alone.

Voriconazole is a potent inhibitor of CYP2C19, CYP2C9, and CYP3A4, making it one of the most interaction-prone drugs in clinical medicine. Key interactions include: tacrolimus and cyclosporine concentrations increased substantially, requiring 50 to 67 percent dose reductions; sirolimus concentrations increased so dramatically that the combination is contraindicated; warfarin augmented through CYP2C9 inhibition of S-warfarin metabolism, requiring close international normalized ratio (INR) monitoring. Strong CYP inducers — rifampin, phenytoin, carbamazepine, long-acting barbiturates, efavirenz — reduce voriconazole concentrations to subtherapeutic levels and are contraindicated or require extraordinary dose adjustment. St. John's wort is also contraindicated.

Voriconazole covers Aspergillus species including Aspergillus terreus, which is resistant to amphotericin B. It is active against most Candida species, Scedosporium apiospermum, and Fusarium species. The major gap is the Mucorales — Rhizopus, Mucor, Lichtheimia — against which voriconazole has no meaningful activity. Clinical experience showed that voriconazole prophylaxis in hematology patients was associated with breakthrough mucormycosis, reinforcing that voriconazole must never be relied on for empirical coverage where Mucorales risk exists.

Three dominant toxicities define voriconazole. Visual disturbances — transient changes in visual acuity, color perception, and photopsia — occur in 20 to 30 percent of patients, beginning within 30 minutes of each dose and resolving within 30 minutes. They are not associated with permanent visual damage with short-term use, but persistent symptoms warrant ophthalmologic evaluation. Hepatotoxicity, manifesting as elevation of liver enzymes, occurs in 5 to 15 percent of patients and is the most common reason for discontinuation. Phototoxic skin reactions with even brief sun exposure occur with prolonged use and are associated in rare cases with squamous cell carcinoma and melanoma, requiring sun protection counseling and annual dermatologic surveillance. Neuropsychiatric effects including hallucinations and encephalopathy occur, particularly at supratherapeutic plasma concentrations.

Isavuconazole is marketed as isavuconazonium sulfate, a water-soluble prodrug rapidly hydrolyzed by plasma esterases after oral or IV administration to release the active isavuconazole. The prodrug design eliminates the need for SBECD in the IV formulation — a meaningful advantage in patients with renal insufficiency who cannot safely receive SBECD-containing IV formulations. Oral bioavailability is approximately 98 percent with no significant food effect, pharmacokinetically superior to both voriconazole (requires fasting) and posaconazole suspension (requires high-fat meal).

Unlike voriconazole, isavuconazole exhibits linear (first-order) pharmacokinetics — plasma concentrations increase proportionally with dose, making pharmacokinetic prediction more reliable. The terminal half-life is approximately 130 hours (five to six days), the longest of the extended-spectrum triazoles, allowing once-daily maintenance dosing. A loading regimen is essential to achieve therapeutic concentrations rapidly in acute infection because steady state without loading takes approximately three weeks.

Isavuconazole inhibits CYP3A4 with somewhat lower potency than voriconazole or posaconazole. Calcineurin inhibitor concentrations are elevated but typically to a lesser degree than with the other extended-spectrum agents; the magnitude of tacrolimus dose reduction required is often smaller. Sirolimus still requires careful TDM. Strong CYP3A4 inducers are contraindicated. A clinically distinctive feature is that isavuconazole shortens the corrected QT interval (QTc) rather than prolonging it — the opposite of most other antifungals and many drugs in general. This is an advantage in patients with baseline QTc prolongation but also a diagnostic signal: QTc shortening on a new electrocardiogram (ECG) in a patient on isavuconazole may indicate supratherapeutic concentrations.

The antifungal spectrum covers Aspergillus species (including Aspergillus terreus), most Candida species, the Mucorales, and the dimorphic fungi. The SECURE trial — a randomized, double-blind, non-inferiority study — demonstrated that isavuconazole was non-inferior to voriconazole for all-cause mortality at day 42 in invasive mold disease, with a significantly better tolerability profile: fewer visual adverse effects, less hepatotoxicity, and fewer skin reactions. A single-arm mucormycosis study (VITAL) demonstrated outcomes comparable to a historical amphotericin B cohort, supporting the mucormycosis approval. Isavuconazole lacks reliable activity against Scedosporium prolificans and some rare non-fumigatus Aspergillus species.

Voriconazole and isavuconazole are both established as first-line therapy for invasive pulmonary aspergillosis in immunocompromised hosts. The SECURE trial established non-inferiority of isavuconazole, and either agent is appropriate as first-line. For CNS aspergillosis, voriconazole remains preferred based on higher published CSF penetration data and extensive clinical experience; isavuconazole is a reasonable alternative when voriconazole is not tolerated. Posaconazole is not first-line for primary treatment of established invasive aspergillosis and is reserved primarily for salvage therapy.

Liposomal amphotericin B remains the preferred primary treatment for mucormycosis given its superior fungicidal activity. Both posaconazole and isavuconazole have demonstrated Mucorales activity and are approved for mucormycosis. They are appropriate for patients who cannot tolerate liposomal amphotericin B, or as step-down oral therapy following initial amphotericin B induction once clinical stabilization is achieved. Oral step-down with an extended-spectrum azole after amphotericin B induction has become standard practice in many centers managing mucormycosis in hematology and transplant patients. Voriconazole must not be used for mucormycosis.

Posaconazole is the preferred agent for prophylaxis in high-risk populations: AML and MDS patients receiving remission-induction chemotherapy, and HSCT recipients with GVHD requiring high-dose corticosteroids or calcineurin inhibitors. The evidence base from randomized trials is strongest for posaconazole in these settings. Voriconazole prophylaxis has been used in some centers for allogeneic HSCT recipients but is not approved for this indication and carries higher drug interaction burden. Isavuconazole has not been studied in large randomized prophylaxis trials and is not a standard prophylaxis agent on current evidence.

When starting any extended-spectrum azole in a transplant patient receiving calcineurin inhibitors, the calcineurin inhibitor dose must be proactively reduced before the azole reaches steady state. A pragmatic approach: reduce tacrolimus to approximately one-third of its usual dose when starting voriconazole or posaconazole, and to approximately one-half with isavuconazole, then titrate based on daily tacrolimus troughs for the first week. Failure to preemptively reduce calcineurin inhibitor doses when azoles are started is a recognized cause of preventable nephrotoxicity and neurotoxicity in transplant recipients. Sirolimus is contraindicated with voriconazole and posaconazole and requires careful TDM with isavuconazole.